Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Today: Africa.
Press releases published on May 5, 2025
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
GlobeNewswire
·
May 5, 2025
Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, …
Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
GlobeNewswire
·
May 5, 2025
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on encouraging high response rates with multiple complete …
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
GlobeNewswire
·
May 5, 2025
SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of …
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
GlobeNewswire
·
May 5, 2025
Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that …
Voreifarem Partners with SwfcNrho Exchange to Create a Global New Paradigm for Medical Data Valuation
GlobeNewswire
·
May 5, 2025
New York, NY, May 05, 2025 (GLOBE NEWSWIRE) -- Recently, Voreifarem, the world’s first digital health project built on the core architecture of "medical chips + blockchain" (token abbreviation: IER), officially launched on the international mainstream …
BigCommerce Taps Technology Industry Veteran with Strong Record of Innovation as Chief Product Officer
GlobeNewswire
·
May 5, 2025
AUSTIN, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands, retailers, manufacturers and distributors, today announced that Vipul Shah has joined the company …
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …
Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
GlobeNewswire
·
May 5, 2025
Builds upon Firefly’s recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “ …
PFMcrypto Launches the Best Free Digital Asset Management Platform in 2025, Attracting Millions Worldwide
GlobeNewswire
·
May 5, 2025
New York, May 05, 2025 (GLOBE NEWSWIRE) -- In a year where passive income is more important than ever, PFMcrypto announces the expansion of its free digital asset management platform, now recognized as the most trusted way to earn passive income without …
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
GlobeNewswire
·
May 5, 2025
– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the …
Hazer and KBR Enter Global Deal to Accelerate Licensing and Commercialisation
GlobeNewswire
·
May 5, 2025
Highlights Binding strategic alliance with KBR (NYSE: KBR), a world-leading engineering group and global technology licensor set to supercharge Hazer’s commercialisation strategy Hazer is KBR’s exclusive partner for marketing and licensing of methane …
Revival Gold Files NI 43-101 Preliminary Economic Assessment for the Mercur Gold Project
GlobeNewswire
·
May 5, 2025
TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”) has filed on SEDAR+ a technical report prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral …
American Tungsten Corp. Announces Changes to Board of Directors
GlobeNewswire
·
May 5, 2025
Vancouver, BC, May 05, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) announces today the appointment of Dan Nicholas to the Board of Directors of the Company (the “Board”), and …
SEALSQ’s VaultIC 408 Meets FIPS 140-3 Requirements, Advancing NIST Certification and Strengthening Leadership in Secure IoT and Smart Grid Solutions
GlobeNewswire
·
May 5, 2025
Geneva, Switzerland, May 05, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced a …
Goliath Resources Engages JDS Energy & Mining Inc. To Forge Plans To Drive An Exploration Adit At Its Surebet Discovery, Golddigger Property, Golden Triangle, B.C.
GlobeNewswire
·
May 5, 2025
Drill-out of all high-grade Surebet lodes will be more easily and cheaply facilitated from underground vantages. Underground access to the Bonanza Zone will enable geological confirmation of this important high-grade lode and potentially enable bulk …
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 5, 2025
—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down …
Regeneration Biomedical to Present Updated Phase 1 Trial Data on Autologous Stem Cell Therapy Injected Directly into the Brain for Alzheimer’s Disease in Podium Presentation at the ISCT 2025 Scientific Annual Meeting
GlobeNewswire
·
May 5, 2025
Abstract selected for a podium presentation and winner of the Host Region (US West) Award First-in-human data now includes five patients, with follow-up ranging from 23 weeks to over a year post-treatment Injections of Wnt-activated, autologous, expanded, …
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswire
·
May 5, 2025
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …
Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
GlobeNewswire
·
May 5, 2025
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- IGI, Inc., a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track …
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference
GlobeNewswire
·
May 5, 2025
WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and …